Small-molecule inhibitors of IL-2/IL-2R: lessons learned and applied.
暂无分享,去创建一个
[1] W. Greene,et al. Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen , 1984, The Journal of experimental medicine.
[2] M. Stahl,et al. Chemical Fragment Spaces for de novo Design. , 2007 .
[3] R. Nussinov,et al. The role of dynamic conformational ensembles in biomolecular recognition. , 2009, Nature chemical biology.
[4] K. Calis,et al. Recombinant interleukin-2: a biological response modifier. , 1991, Clinical pharmacy.
[5] Edgar Jacoby,et al. Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.
[6] A. Ridderstad,et al. Cytokines in rheumatoid arthritis. , 1991, Annals of medicine.
[7] Volkhard Helms,et al. What induces pocket openings on protein surface patches involved in protein–protein interactions? , 2009, J. Comput. Aided Mol. Des..
[8] H. Morris,et al. Amino acid sequence and post-translational modification of human interleukin 2. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[9] F. Hagemeister,et al. Denileukin diftitox: a novel immunotoxin , 2009, Expert opinion on biological therapy.
[10] R. Lier,et al. Common γ chain cytokines: Dissidence in the details , 2007 .
[11] B. Rouse,et al. Regulatory Cells and Infectious Agents: Détentes Cordiale and Contraire , 2004, The Journal of Immunology.
[12] Chris Abell,et al. Fragment-based approaches to enzyme inhibition. , 2007, Current opinion in biotechnology.
[13] Xuetao Cao,et al. Interleukin-17 and its expanding biological functions , 2010, Cellular and Molecular Immunology.
[14] D. Delgado,et al. The promise of C2, Simulect, and Certican in heart transplantation. , 2004, Transplantation proceedings.
[15] K. McKeage,et al. Basiliximab: a review of its use as induction therapy in renal transplantation. , 2010, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
[16] J. Lear,et al. A new data analysis method to determine binding constants of small molecules to proteins using equilibrium analytical ultracentrifugation with absorption optics. , 2001, Analytical biochemistry.
[17] Nir London,et al. The structural basis of peptide-protein binding strategies. , 2010, Structure.
[18] R. Gallo,et al. Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.
[19] M. Goldsmith,et al. The molecular role of the common gamma c subunit in signal transduction reveals functional asymmetry within multimeric cytokine receptor complexes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[20] T. Waldmann,et al. The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases , 2002, Arthritis research.
[21] N. Tanaka,et al. Cloning of the gamma chain of the human IL-2 receptor. , 1992, Science.
[22] Peter Ertl,et al. Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions , 2009, J. Cheminformatics.
[23] Thomas Singer,et al. The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.
[24] M. Masri. The mosaic of immunosuppressive drugs. , 2003, Molecular immunology.
[25] D. Fry,et al. NMR characterization of interleukin‐2 in complexes with the IL‐2Rα receptor component, and with low molecular weight compounds that inhibit the IL‐2/IL‐Rα interaction , 2003, Protein science : a publication of the Protein Society.
[26] P. Sellier,et al. Interleukin-2 therapy in patients with HIV infection. , 2010, The New England journal of medicine.
[27] Olivier Sperandio,et al. Rationalizing the chemical space of protein-protein interaction inhibitors. , 2010, Drug discovery today.
[28] Dorothea Busse,et al. Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments , 2010, Proceedings of the National Academy of Sciences.
[29] N. Tanaka,et al. The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. , 1996, Annual review of immunology.
[30] Xavier Morelli,et al. Protein-protein interaction inhibition (2P2I): fewer and fewer undruggable targets. , 2009, Combinatorial chemistry & high throughput screening.
[31] Erinna F. Lee,et al. Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family , 2007, Cell Death and Differentiation.
[32] T. van Gelder,et al. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice? , 2004, Drugs.
[33] Glyn Williams,et al. Fragment-based screening using X-ray crystallography and NMR spectroscopy. , 2007, Current opinion in chemical biology.
[34] Christopher L. McClendon,et al. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.
[35] S. Feng,et al. Optimizing the use of cyclosporine (Neoral) for recipients of living donor kidneys. , 2004, Transplantation proceedings.
[36] A. Balcerska,et al. Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. , 2008, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[37] J. Thornton,et al. A method for localizing ligand binding pockets in protein structures , 2005, Proteins.
[38] M. Sayegh,et al. The role of costimulatory molecules as targets for new immunosuppressives in transplantation. , 2000, Current opinion in urology.
[39] D. Brennan,et al. Current and Future Immunosuppressive Strategies in Renal Transplantation , 2004, Pharmacotherapy.
[40] A. Rudensky,et al. Control of regulatory T cell lineage commitment and maintenance. , 2009, Immunity.
[41] Y. Yamamura,et al. The IL-2 receptor beta-chain (p70). Ligand binding ability of the cDNA-encoding membrane and secreted forms. , 1990, Journal of immunology.
[42] Cornel Catana,et al. Inhibition of protein–protein interactions: The discovery of druglike β‐catenin inhibitors by combining virtual and biophysical screening , 2006, Proteins.
[43] C. Ponticelli. Cyclosporine: From Renal Transplantation to Autoimmune Diseases , 2005, Annals of the New York Academy of Sciences.
[44] B. Nashan. The interleukin-2 inhibitors and their role in low-toxicity regimens. , 1999, Transplantation proceedings.
[45] Michelle R. Arkin,et al. Binding of small molecules to an adaptive protein–protein interface , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[46] B. Bielekova,et al. Monoclonal antibodies in MS , 2010, Neurology.
[47] Roderick E Hubbard,et al. Fragment-based ligand discovery. , 2009, Molecular interventions.
[48] E. Geissler,et al. mTOR, Cancer and Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[49] S. Gaffen. Signaling domains of the interleukin 2 receptor. , 2001, Cytokine.
[50] Matthew A Burchill,et al. Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. , 2007, Immunology letters.
[51] D. Fattori,et al. Fragment-Based Approach to Drug Lead Discovery , 2008, Drugs in R&D.
[52] Suzanne C Brewerton,et al. The use of protein-ligand interaction fingerprints in docking. , 2008, Current opinion in drug discovery & development.
[53] David C Fry,et al. Protein-protein interactions as targets for small molecule drug discovery. , 2006, Biopolymers.
[54] Jonathan C. Fuller,et al. Predicting druggable binding sites at the protein-protein interface. , 2009, Drug discovery today.
[55] M. Bevan,et al. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. , 2010, Immunity.
[56] Anne S De Groot,et al. Immunogenicity of protein therapeutics. , 2007, Trends in immunology.
[57] Marc-André Delsuc,et al. Biophysical techniques for ligand screening and drug design. , 2009, Current opinion in pharmacology.
[58] Dima Kozakov,et al. Convergence and combination of methods in protein-protein docking. , 2009, Current opinion in structural biology.
[59] P. Kollman,et al. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .
[60] Christopher D. Thanos,et al. Hot-spot mimicry of a cytokine receptor by a small molecule , 2006, Proceedings of the National Academy of Sciences.
[61] J. Dunn. Review of immunosuppressive drug therapy in uveitis , 2004, Current opinion in ophthalmology.
[62] P. Jhurani,et al. Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis. , 1989, Science.
[63] S. Korsmeyer,et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.
[64] Kristin E. D. Coan,et al. Promiscuous Aggregate-Based Inhibitors Promote Enzyme Unfolding , 2009, Journal of medicinal chemistry.
[65] Christopher W Murray,et al. Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.
[66] A Wlodawer,et al. Structural comparisons among the short-chain helical cytokines. , 1994, Structure.
[67] T. Waldmann,et al. Phorbol diester induces expression of Tac antigen on human acute T lymphocytic leukemic cells. , 1984, Journal of immunology.
[68] Maria A Miteva,et al. Structure-based virtual ligand screening: recent success stories. , 2009, Combinatorial chemistry & high throughput screening.
[69] S. Sandrini. Use of IL‐2 receptor antagonists to reduce delayed graft function following renal transplantation: a review , 2005, Clinical transplantation.
[70] S. Stauffer,et al. Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737. , 2007, Current topics in medicinal chemistry.
[71] Iain B McInnes,et al. Evidence that cytokines play a role in rheumatoid arthritis. , 2008, The Journal of clinical investigation.
[72] A. Church. Clinical advances in therapies targeting the interleukin-2 receptor. , 2003, QJM : monthly journal of the Association of Physicians.
[73] Dima Kozakov,et al. Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques , 2009, Bioinform..
[74] J. Tavernier,et al. Cloning and structure of the human interleukin 2 chromosomal gene. , 1983, The EMBO journal.
[75] M. Randal,et al. Potent small-molecule binding to a dynamic hot spot on IL-2. , 2003, Journal of the American Chemical Society.
[76] Sylvia E Kim. Daclizumab Treatment for Multiple Sclerosis , 2009, Pharmacotherapy.
[77] W. Delano. The PyMOL Molecular Graphics System , 2002 .
[78] L. Vassilev,et al. MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.
[79] Daniel A Erlanson,et al. Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly. , 2004, Current opinion in chemical biology.
[80] P. Gregersen,et al. Structural biology of shared cytokine receptors. , 2009, Annual review of immunology.
[81] Roland Martin. Humanized Anti-CD25 Antibody Treatment with Daclizumab in Multiple Sclerosis , 2007, Neurodegenerative Diseases.
[82] Bert L. de Groot,et al. Ligand docking and binding site analysis with PyMOL and Autodock/Vina , 2010, J. Comput. Aided Mol. Des..
[83] M. Uesugi,et al. [Discovering high-affinity ligands for proteins: SAR by NMR]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.
[84] R. V. van Montfort,et al. Structure-based design of molecular cancer therapeutics. , 2009, Trends in biotechnology.
[85] V. Fung,et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. , 1994, Science.
[86] J. Watson,et al. Molecular Characterization of Interleukin 2 , 1982, Federation proceedings.
[87] K. Audouze,et al. Emerging classes of protein-protein interaction inhibitors and new tools for their development. , 2004, Current opinion in chemical biology.
[88] G. Ju,et al. Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[89] Mark Whittaker,et al. The multiple roles of computational chemistry in fragment-based drug design , 2009, J. Comput. Aided Mol. Des..
[90] R. Nussinov,et al. Protein–protein interactions: Structurally conserved residues distinguish between binding sites and exposed protein surfaces , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[91] V. Helms,et al. Transient pockets on protein surfaces involved in protein-protein interaction. , 2007, Journal of medicinal chemistry.
[92] C. Poirier. Promise of Neoral C2, basiliximab, and everolimus in lung transplantation. , 2004, Transplantation proceedings.
[93] G. Powers,et al. Identification of a Small Molecule Inhibitor of the IL-2/IL-2Rα Receptor Interaction Which Binds to IL-2 , 1997 .
[94] Anthony M Giannetti,et al. Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. , 2008, Journal of medicinal chemistry.
[95] G. Crabtree,et al. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor , 1984, Nature.
[96] A. Feller,et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene , 1993, Cell.
[97] Harald Schwalbe,et al. Perspectives on NMR in drug discovery: a technique comes of age , 2008, Nature Reviews Drug Discovery.
[98] W. Leonard,et al. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines , 2000, Oncogene.
[99] A. Le Moine,et al. Interleukin 17-producing T helper cells in alloimmunity. , 2009, Transplantation reviews.
[100] T. Taniguchi,et al. Structure and expression of a cloned cDNA for human interleukin-2 , 1983, Nature.
[101] Michelle R. Arkin,et al. Discovery and characterization of cooperative ligand binding in the adaptive region of interleukin-2 , 2002 .
[102] G. Tsokos,et al. Transcriptional regulation of IL-2 in health and autoimmunity. , 2009, Autoimmunity reviews.
[103] David L Mobley,et al. Quantifying Correlations Between Allosteric Sites in Thermodynamic Ensembles. , 2009, Journal of chemical theory and computation.
[104] Gianni Chessari,et al. From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.
[105] M. Arkin,et al. Identification of nonpeptidic small-molecule inhibitors of interleukin-2. , 2005, Bioorganic & medicinal chemistry letters.
[106] P. Karakiewicz,et al. Treatment of metastatic renal cell carcinoma , 2010, Nature Reviews Urology.
[107] A. Balcerska,et al. Serum soluble interleukin 2 receptor α in human cancer of adults and children: a review , 2008 .
[108] G. Chinnadurai,et al. BH3-only proteins in apoptosis and beyond: an overview , 2008, Oncogene.
[109] S. Brouard,et al. Interleukin 7 receptor α as a potential therapeutic target in transplantation , 2009, Archivum Immunologiae et Therapiae Experimentalis.
[110] Mitchell A. Avery,et al. Targeting the BH3 Domain Mediated Protein-Protein Interaction of Bcl-xL through Virtual Screening , 2010, J. Chem. Inf. Model..
[111] G. Siegal,et al. Fragment‐Based Synthesis and SAR of Modified FKBP Ligands: Influence of Different Linking on Binding Affinity , 2007, ChemMedChem.
[112] J. Bazan,et al. Structural design and molecular evolution of a cytokine receptor superfamily. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[113] T. Olencki,et al. Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response. , 1997, Journal of immunotherapy.
[114] K. Garcia,et al. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. , 2005, Science.
[115] Kendall A. Smith,et al. Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. , 2010, Immunity.
[116] T. Taniguchi,et al. IL‐2 Signaling Involves Recruitment and Activation of Multiple Protein Tyrosine Kinases by the IL‐2 Receptor a , 1995, Annals of the New York Academy of Sciences.
[117] D. Mckay,et al. Three-dimensional structure of interleukin-2. , 1987, Science.
[118] Helgi B. Schiöth,et al. Structural diversity of G protein-coupled receptors and significance for drug discovery , 2008, Nature Reviews Drug Discovery.
[119] Scott P. Brown,et al. Effects of Conformational Dynamics on Predicted Protein Druggability , 2006, ChemMedChem.
[120] Wei Gu,et al. Modes of p53 Regulation , 2009, Cell.
[121] Heather A Carlson,et al. Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. , 2007, Journal of the American Chemical Society.
[122] A. Kirk,et al. A New Look at Blockade of T‐cell Costimulation: A Therapeutic Strategy for Long‐term Maintenance Immunosuppression , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[123] M. Parkes,et al. Contribution of the IL‐2 and IL‐10 genes to inflammatory bowel disease (IBD) susceptibility , 1998, Clinical and experimental immunology.
[124] T. Taniguchi,et al. Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's. , 1989, Science.
[125] Yongbo Hu,et al. Comparison of Several Molecular Docking Programs: Pose Prediction and Virtual Screening Accuracy , 2009, J. Chem. Inf. Model..
[126] Thomas D. Goddard,et al. Visualization software for molecular assemblies. , 2007, Current opinion in structural biology.
[127] W. Koltun,et al. THE EFFECT OF ANTI‐INTERLEUKIN-2 RECEPTOR MONOCLONAL ANTIBODY ON ALLOGRAFT REJECTION , 1985, Transplantation.
[128] Chris Abell,et al. Drugging challenging targets using fragment-based approaches. , 2010, Current opinion in chemical biology.
[129] P. Hajduk,et al. Druggability indices for protein targets derived from NMR-based screening data. , 2005, Journal of medicinal chemistry.
[130] W. Delano,et al. In situ assembly of enzyme inhibitors using extended tethering , 2003, Nature Biotechnology.
[131] Burkhard Rost,et al. Protein–Protein Interaction Hotspots Carved into Sequences , 2007, PLoS Comput. Biol..
[132] I. Enyedy,et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. , 2001, Journal of medicinal chemistry.
[133] J. Hardy,et al. Dissecting an Allosteric Switch in Caspase-7 Using Chemical and Mutational Probes* , 2009, The Journal of Biological Chemistry.
[134] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[135] [Amino acid sequence]. , 1970, Deutsche medizinische Wochenschrift.
[136] W. Leonard,et al. The Human Interleukin‐2 Receptor: Analysis of Structure and Function , 1986, Immunological reviews.
[137] Michèle N Schulz,et al. Recent progress in fragment-based lead discovery. , 2009, Current opinion in pharmacology.
[138] J. Metcalf,et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. , 1996, The New England journal of medicine.
[139] Kendall A. Smith,et al. Quantitation, Specificity, and Biological Relevance* , 1981 .
[140] W. Delano. Unraveling hot spots in binding interfaces: progress and challenges. , 2002, Current opinion in structural biology.
[141] Brett A Tounge,et al. The role of molecular size in ligand efficiency. , 2007, Bioorganic & medicinal chemistry letters.
[142] A. Munck,et al. T cell growth factor receptors. Quantitation, specificity, and biological relevance , 1981, The Journal of experimental medicine.
[143] H. Wolfson,et al. Access the most recent version at doi: 10.1110/ps.21302 References , 2001 .
[144] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[145] J. Johnston,et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. , 1994, Science.
[146] B. Nelson,et al. Biology of the interleukin-2 receptor. , 1998, Advances in immunology.
[147] J. A. Grant,et al. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. , 2005, Journal of medicinal chemistry.
[148] W. Delano,et al. Convergent solutions to binding at a protein-protein interface. , 2000, Science.
[149] Kendall A. Smith,et al. The quantal theory of immunity and the interleukin‐2‐dependent negative feedback regulation of the immune response , 2008, Immunological reviews.
[150] C. Ensor,et al. Induction Immunosuppression for Orthotopic Heart Transplantation: A Review , 2009, Progress in transplantation.
[151] K. Christopher Garcia,et al. The Structure of Interleukin-2 Complexed with Its Alpha Receptor , 2005, Science.
[152] T. Malek,et al. The biology of interleukin-2. , 2008, Annual review of immunology.
[153] D. Barford,et al. Lining the pockets of kinases and phosphatases. , 2006, Current opinion in structural biology.
[154] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[155] J. Watson,et al. Molecular characterization of interleukin 2. , 1982, Immunological reviews.
[156] P. Nowell. Phytohemagglutinin: an initiator of mitosis in cultures of normal human leukocytes. , 1960, Cancer research.
[157] Olivier Sperandio,et al. Designing Focused Chemical Libraries Enriched in Protein-Protein Interaction Inhibitors using Machine-Learning Methods , 2010, PLoS Comput. Biol..
[158] J. Platt,et al. Escaping from rejection. , 2009, Transplantation.
[159] Magnus Björsne,et al. Label-Free Primary Screening and Affinity Ranking of Fragment Libraries Using Parallel Analysis of Protein Panels , 2008, Journal of biomolecular screening.
[160] R. Stroud,et al. Site-directed ligand discovery. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[161] Kristin E. D. Coan,et al. Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. , 2008, Journal of the American Chemical Society.
[162] Jeffrey Aubé,et al. Structural analysis of β-turn mimics containing a substituted 6-aminocaproic acid linker , 1995 .
[163] H. Jhoti,et al. Structure-based screening of low-affinity compounds. , 2002, Drug discovery today.
[164] Andrew C. Chan,et al. Therapeutic antibodies for autoimmunity and inflammation , 2010, Nature Reviews Immunology.
[165] M. Kanehisa,et al. Structure of the human interleukin-2 receptor gene. , 1985, Science.
[166] Jianping Ding,et al. Structural Basis for the Blockage of IL-2 Signaling by Therapeutic Antibody Basiliximab , 2009, The Journal of Immunology.
[167] S. Rosenberg,et al. Systemic administration of interleukin-2 in humans. , 1984, Journal of biological response modifiers.
[168] Conrad C. Huang,et al. UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..
[169] D. Kostrewa,et al. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. , 2000, Journal of medicinal chemistry.
[170] Aurélien Grosdidier,et al. Docking, virtual high throughput screening and in silico fragment-based drug design , 2009, Journal of cellular and molecular medicine.
[171] Jian Sun,et al. Fragment-based discovery of nonpeptidic BACE-1 inhibitors using tethering. , 2009, Biochemistry.
[172] Michelle R. Arkin,et al. Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.
[173] Kendall A. Smith,et al. T‐Cell Growth Factor , 1980, Immunological reviews.
[174] Michelle R Arkin,et al. Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. , 2003, Journal of the American Chemical Society.
[175] R. Nussinov,et al. The origin of allosteric functional modulation: multiple pre-existing pathways. , 2009, Structure.
[176] D. Chistiakov,et al. The crucial role of IL-2/IL-2RA-mediated immune regulation in the pathogenesis of type 1 diabetes, an evidence coming from genetic and animal model studies. , 2008, Immunology letters.
[177] M. Bevan,et al. Effector and memory CTL differentiation. , 2007, Annual review of immunology.
[178] Fergal P. Casey,et al. Discovery of Small Molecule Inhibitors of Protein-Protein Interactions Using Combined Ligand and Target Score Normalization , 2009, J. Chem. Inf. Model..
[179] Daniel A Erlanson,et al. Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry. , 2008, Bioorganic & medicinal chemistry letters.
[180] Daniel A Erlanson,et al. Discovery of a new phosphotyrosine mimetic for PTP1B using breakaway tethering. , 2003, Journal of the American Chemical Society.
[181] W. Leonard,et al. Cytokines and immunodeficiency diseases: critical roles of the γc‐dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways , 2004, Immunological reviews.
[182] L. Mario Amzel,et al. Impact of linker strain and flexibility in the design of a fragment-based inhibitor , 2009, Nature chemical biology.
[183] Michelle R Arkin,et al. Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions. , 2004, Journal of medicinal chemistry.
[184] J. Bertoglio,et al. Recent Advances in the Understanding of Interleukin-2 Signal Transduction , 1998, Journal of Clinical Immunology.
[185] W. Leonard,et al. Characterization of the human interleukin-2 receptor gamma chain gene. , 1993, The Journal of biological chemistry.
[186] T. Waldmann,et al. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. , 2008, Journal of autoimmunity.
[187] T. Waldmann,et al. Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. , 1989, Transplantation.
[188] M. Swindells,et al. Protein clefts in molecular recognition and function. , 1996, Protein science : a publication of the Protein Society.